吡格列酮
安慰剂
阳性与阴性症状量表
利培酮
精神分裂症(面向对象编程)
内科学
医学
随机对照试验
不利影响
精神病
精神科
内分泌学
糖尿病
2型糖尿病
病理
替代医学
作者
Negar Iranpour,Atefeh Zandifar,Mehdi Farokhnia,Amirhossein Goguol,Habibeh Yekehtaz,Mohammad Reza Khodaie Ardakani,Bahman Salehi,Sophia Esalatmanesh,Atefeh Zeionoddini,Payam Mohammadinejad,Atefeh Zeinoddini,Shahin Akhondzadeh
摘要
Objective The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti‐inflammatory and antioxidant properties. In this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia. Methods In this randomized, double‐blind, placebo‐controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks. Patients' symptoms and adverse events were rated at baseline and weeks 2, 4, 6, and 8. The difference between the two groups in decline of PANSS negative subscale scores was considered as the primary outcome of this study. Results At the study endpoint, patients in the pioglitazone group showed significantly more improvement in PANSS negative subscale scores ( p < 0.001) as well as PANSS total scores ( p = 0.01) compared with the placebo group. Conclusion These findings suggest the probable efficacy of pioglitazone as an augmentation therapy in reducing the negative symptoms of schizophrenia. Copyright © 2016 John Wiley & Sons, Ltd.
科研通智能强力驱动
Strongly Powered by AbleSci AI